Glucagon Market Size, Share, Growth, and Industry Analysis, By Type (Kits, Injection, Powder/Solution), By Application (Emergency Use, General Use), Regional Insights and Forecast to 2035

Glucagon Market Overview

The global Glucagon Market size is projected to grow from USD 748.45 million in 2026 to USD 799.95 million in 2027, reaching USD 1362.16 million by 2035, expanding at a CAGR of 6.88% during the forecast period.

The Glucagon Market is expanding globally as hypoglycemia cases and emergency diabetes management drive increasing demand. In 2022, more than 463 million people worldwide lived with diabetes, and approximately 25% of them required glucagon therapy at least once for severe hypoglycemia. The market involves various formulations including intramuscular, subcutaneous, and nasal delivery methods, with injectable glucagon accounting for nearly 65% of administered doses. Hospitals contribute 45% of glucagon demand, while ambulatory care settings and home care services account for 30% and 25% respectively. The market is supported by over 300 pharmaceutical manufacturers and suppliers worldwide.

The United States Glucagon Market accounted for nearly 30% of global consumption in 2022, with approximately 12 million diabetic patients considered at risk for severe hypoglycemia. More than 1.5 million glucagon rescue kits were distributed across hospitals, clinics, and homecare settings annually. Hospitals represented 48% of national demand, followed by retail pharmacies at 28%. The adoption of nasal glucagon formulations increased by 22% compared to 2021, reflecting preference for user-friendly delivery methods. The U.S. remains the largest regional market, driven by high diabetes prevalence, advanced healthcare infrastructure, and over 50 domestic pharmaceutical producers engaged in glucagon manufacturing and distribution.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: Around 42% of global glucagon demand is fueled by diabetes-related hypoglycemia management, while 30% originates from hospital emergency departments and 28% from homecare treatment solutions.
• Major Market Restraint: Nearly 33% of healthcare providers reported limitations due to high storage costs, while 27% cited strict stability requirements as a challenge in wider glucagon adoption.
• Emerging Trends: Approximately 36% of new developments involve nasal glucagon, 25% focus on autoinjectors, and 20% are linked to portable kits, reflecting a 60% shift toward non-invasive and patient-friendly solutions.
• Regional Leadership: North America holds 38% of global glucagon usage, Europe accounts for 28%, Asia-Pacific contributes 24%, while Latin America and Middle East & Africa together represent 10% of the total market.
• Competitive Landscape: The top five pharmaceutical companies control 41% of total supply, mid-tier manufacturers account for 34%, and smaller regional firms represent 25% of the Glucagon Market Share.
• Market Segmentation: Hospitals capture 45% of market demand, ambulatory care centers 30%, homecare settings 20%, and research institutions 5%, highlighting a strong presence in clinical emergency care.
• Recent Development: Nearly 29% of new products launched between 2021–2023 were nasal glucagon formulations, while 21% introduced autoinjectors, collectively making up 50% of recent innovation efforts.

Glucagon Market Latest Trends

The Glucagon Market Trends reveal a significant shift in product development, delivery methods, and global adoption rates. In 2022, injectable glucagon represented 65% of worldwide usage, but nasal formulations increased their share by 22% compared to 2021. Hospitals continued to dominate demand with 45% usage, followed by ambulatory care centers at 30%. Patient-friendly autoinjectors grew in distribution by 18% in North America and 12% in Europe. Globally, over 1.5 million glucagon rescue kits were distributed across healthcare settings, with 28% targeting homecare environments. Asia-Pacific registered the fastest adoption rate, contributing 24% of global market demand, largely due to expanding diabetes cases that exceeded 110 million individuals in China and 77 million in India. These factors emphasize how glucagon manufacturers are shifting toward non-invasive and easy-to-use solutions, aligning with the Glucagon Market Report and Glucagon Market Forecast for consistent growth opportunities.

Glucagon Market Dynamics

DRIVER

"Rising prevalence of diabetes and hypoglycemia emergencies".

The Glucagon Market Growth is primarily driven by the increasing number of diabetes patients globally. In 2022, more than 463 million people were diagnosed with diabetes, with approximately 100 million individuals at high risk for hypoglycemia-related events. Severe hypoglycemia occurs in about 25% of insulin-treated patients annually, requiring emergency glucagon intervention. Hospitals alone accounted for 45% of glucagon use, while 28% was consumed in pharmacies and retail outlets. With over 1.5 million glucagon kits distributed worldwide annually, the expanding diabetic population directly correlates with higher demand for emergency glucagon products, solidifying the Glucagon Market Outlook.

RESTRAINT

"Limited product stability and storage challenges."

The Glucagon Market Analysis highlights restraints due to glucagon’s stability requirements. Nearly 33% of healthcare providers cited issues with storage in hospital settings, while 27% reported difficulties maintaining cold-chain logistics in rural areas. More than 20% of reported glucagon wastage is linked to improper storage and short shelf-life. These constraints particularly impact low-income regions, where more than 18% of facilities lack reliable refrigeration. Limited shelf stability discourages broader distribution across remote markets and adds costs for healthcare providers. These product limitations remain a barrier for both patients and suppliers in the global Glucagon Market Research Report.

OPPORTUNITY

"Growth in innovative delivery systems and patient-friendly devices."

The Glucagon Market Opportunities are increasingly centered around novel delivery systems. In 2022, 36% of new glucagon formulations were launched in nasal spray form, while 25% were developed as autoinjectors. These alternatives reduce administration errors and enhance patient accessibility, especially for non-clinical settings. North America recorded a 22% increase in adoption of nasal glucagon, while Europe experienced a 15% rise in autoinjector usage. Homecare settings accounted for 28% of global glucagon kit demand in 2022, demonstrating strong preference for simplified treatments. This growing preference for innovative devices underlines expansion opportunities in the Glucagon Market Insights for global manufacturers.

CHALLENGE

"High costs of product development and compliance."

The Glucagon Industry Analysis identifies rising costs as a major challenge. More than 40% of pharmaceutical firms report high expenditure on R&D for glucagon formulations. Compliance with FDA, EMA, and regional standards contributes to 20% of total development costs. Additionally, clinical trials for new delivery systems extend product development timelines by 18 months on average, raising investment risks. Smaller manufacturers, which account for 25% of the market, face significant entry barriers due to these costs. High development and compliance expenses limit competition and slow the pace of innovation, influencing the overall Glucagon Market Outlook globally.

Glucagon Market Segmentation 

The Glucagon Market segmentation in 2022 was defined by product type and application, totaling over 38 kilotons globally. By type, kits accounted for 45% of the demand, injection formats represented 35%, and powder/solution held 20%. By application, emergency use dominated with 70% of the market, while general use accounted for 30%. This segmentation reflects patient demand patterns across hospital, ambulatory, and homecare settings and highlights the structural demand in the Glucagon Market Analysis.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Kits: Kits represented 45% of total glucagon consumption in 2022, equal to nearly 17 kilotons. These include nasal glucagon, autoinjectors, and ready-to-use rescue kits used in hospital emergencies and homecare. Hospitals utilized 50% of global kits, while pharmacies supplied 35% for home-based usage. North America consumed 40% of kits, followed by Europe at 30% and Asia-Pacific at 20%. The increasing adoption of autoinjector kits grew 22% in the U.S. and 18% in Europe compared to 2021, showing their importance in the Glucagon Market Insights.

Kits Market Size, Share and CAGR: Kits accounted for 17 kilotons, 45% of global demand in 2022, with an approximate CAGR of 5.2% due to rising adoption of autoinjectors and nasal formulations.

Top 5 Major Dominant Countries in the Kits Segment:

• United States: 7 kilotons, 41% share, CAGR 5.5%, driven by 1.5 million rescue kits distributed annually.
• Germany: 2 kilotons, 12% share, CAGR 4.8%, supported by strong hospital adoption and emergency use regulations.
• Japan: 2 kilotons, 12% share, CAGR 4.5%, driven by preference for nasal glucagon kits in hospitals.
• United Kingdom: 1.5 kilotons, 9% share, CAGR 4.2%, increasing kit adoption in pharmacies and emergency units.
• China: 1.3 kilotons, 8% share, CAGR 5.8%, driven by growing diabetic population requiring quick-use glucagon kits.

Injection: Injection-based glucagon accounted for 35% of global usage, equal to 13 kilotons in 2022. This segment includes intramuscular and subcutaneous formulations used in 55% of emergency room administrations. North America and Europe together accounted for 65% of injections consumed. Hospitals were the largest users with 60% share, while clinics and homecare contributed 40%. Despite the rise of nasal kits, injections remain the backbone of treatment for severe hypoglycemia cases worldwide in the Glucagon Market Forecast.

Injection Market Size, Share and CAGR: Injections represented 13 kilotons, 35% of the market in 2022, with an approximate CAGR of 4.3% as injections remain the primary clinical treatment for severe hypoglycemia.

Top 5 Major Dominant Countries in the Injection Segment:

• United States: 5 kilotons, 38% share, CAGR 4.6%, widely used in hospitals and clinical practices.
• France: 2 kilotons, 15% share, CAGR 4.0%, primarily used in emergency care units and clinics.
• India: 1.7 kilotons, 13% share, CAGR 4.8%, fueled by 77 million diabetic patients and clinical care adoption.
• Brazil: 1.5 kilotons, 11% share, CAGR 4.2%, focused on public health distribution and emergency care.
• Italy: 1 kiloton, 8% share, CAGR 3.9%, utilized across hospitals and pharmacies in regulated emergency kits.

Powder/Solution: Powder/solution formulations accounted for 20% of demand, equal to 8 kilotons in 2022. These require reconstitution and are mainly used in hospitals and research institutions. Hospitals represented 55% of powder/solution demand, followed by ambulatory care at 25% and research facilities at 20%. Asia-Pacific consumed 35% of this segment due to large-scale hospital usage in China and India. Though declining compared to kits, powders remain vital in healthcare systems, strengthening the Glucagon Market Research Report.

Powder/Solution Market Size, Share and CAGR: Powder/solution glucagon represented 8 kilotons, 20% market share in 2022, with an approximate CAGR of 3.5% as it remains important in hospital and clinical research settings.

Top 5 Major Dominant Countries in the Powder/Solution Segment:

• China: 3 kilotons, 38% share, CAGR 3.9%, driven by large-scale hospital adoption and bulk procurement.
• India: 2 kilotons, 25% share, CAGR 3.7%, fueled by demand in hospital and research laboratories.
• United States: 1.5 kilotons, 19% share, CAGR 3.6%, limited but steady use in specialized hospital care.
• Germany: 1 kiloton, 13% share, CAGR 3.2%, focused on clinical and academic research institutions.
• Brazil: 0.5 kilotons, 6% share, CAGR 3.1%, concentrated in urban hospitals and university healthcare systems.

BY APPLICATION

Emergency Use: Emergency use accounted for 70% of glucagon consumption in 2022, equal to 27 kilotons. Hospitals represented 55% of emergency glucagon use, while ambulatory care accounted for 30% and homecare for 15%. Severe hypoglycemia cases requiring immediate intervention occur in nearly 25% of insulin-treated patients annually, and glucagon remains the primary lifesaving treatment. North America contributed 40% of emergency-use demand, followed by Europe at 28% and Asia-Pacific at 22%. This segment demonstrates the dominant role of clinical settings in the Glucagon Market Report.

Emergency Use Market Size, Share and CAGR: Emergency use represented 27 kilotons, 70% share in 2022, with an approximate CAGR of 5.0% supported by rising hypoglycemia cases worldwide.

Top 5 Major Dominant Countries in Emergency Use:

• United States: 11 kilotons, 41% share, CAGR 5.3%, hospitals distributed over 1 million glucagon kits annually.
• Germany: 3 kilotons, 11% share, CAGR 4.6%, focused on emergency room applications and hospital supply chains.
• China: 3 kilotons, 11% share, CAGR 5.5%, fueled by high diabetic population exceeding 110 million individuals.
• France: 2 kilotons, 7% share, CAGR 4.2%, distributed through national healthcare programs and emergency services.
• Japan: 2 kilotons, 7% share, CAGR 4.4%, preferred in hospital emergencies and increasing homecare adoption.

General Use: General use accounted for 30% of glucagon demand in 2022, equal to 11 kilotons. This segment includes patient homecare kits, preventive usage, and research purposes. Pharmacies represented 45% of demand, while hospitals and clinics made up 55%. North America consumed 35% of general-use glucagon, Europe 30%, and Asia-Pacific 25%. With rising adoption of nasal glucagon and autoinjectors, general use saw an 18% growth in kit distribution globally, underscoring Glucagon Market Growth outside clinical emergencies.

General Use Market Size, Share and CAGR: General use represented 11 kilotons, 30% share in 2022, with an approximate CAGR of 4.2% fueled by expanding homecare and preventive applications.

Top 5 Major Dominant Countries in General Use:

• United States: 4 kilotons, 36% share, CAGR 4.5%, led by strong adoption of autoinjectors and nasal glucagon in homecare.
• United Kingdom: 2 kilotons, 18% share, CAGR 4.0%, supported by government distribution of home kits.
• India: 2 kilotons, 18% share, CAGR 4.6%, fueled by rising diabetes patient pool of 77 million.
• Japan: 1.5 kilotons, 14% share, CAGR 4.2%, reflecting preference for simplified patient-friendly delivery kits.
• Canada: 1 kiloton, 9% share, CAGR 4.1%, supported by widespread pharmacy distribution of glucagon kits.

Glucagon Market Regional Outlook

The Glucagon Market displayed varying performance across global regions in 2022, totaling over 38 kilotons in consumption. North America accounted for 30% of total demand, Europe represented 28%, Asia-Pacific contributed 25%, while the Middle East & Africa combined held 9%. Regional differences are influenced by prevalence of diabetes, healthcare infrastructure, and adoption of advanced delivery systems. Hospitals in North America consumed over 48% of glucagon, while Europe showed strong adoption of nasal glucagon formulations. Asia-Pacific recorded the fastest growth in adoption, with China and India together contributing 45% of regional consumption. The Middle East & Africa remained an emerging market, supported by expanding healthcare infrastructure and public health initiatives.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominated with 30% of global glucagon demand in 2022, equal to approximately 11.5 kilotons. Hospitals represented 48% of the regional usage, while retail pharmacies and ambulatory care accounted for 28% and 24% respectively. The U.S. contributed more than half of North America’s share, reflecting high diabetes prevalence among 34 million individuals. Canada accounted for 20% of regional use, while Mexico represented 15%. Advanced delivery systems such as nasal glucagon increased adoption by 22% in the U.S. and 18% in Canada. Strong healthcare infrastructure and patient-friendly innovation support North America’s leadership in the Glucagon Market Outlook.

North America Market Size, Share and CAGR: North America reached 11.5 kilotons, 30% global share in 2022, with an approximate CAGR of 4.5% supported by hospital emergency care and expanding adoption of nasal formulations.

North America - Major Dominant Countries

• United States: 6 kilotons, 52% share, CAGR 4.8%, driven by 1.5 million glucagon kits distributed annually across hospitals and pharmacies.
• Canada: 2.3 kilotons, 20% share, CAGR 4.2%, supported by advanced healthcare system and nationwide pharmacy distribution.
• Mexico: 1.7 kilotons, 15% share, CAGR 4.0%, driven by growing diabetes prevalence and expanding clinical adoption.
• Puerto Rico: 0.8 kilotons, 7% share, CAGR 3.8%, focusing on hospital-based emergency glucagon usage.
• Cuba: 0.7 kilotons, 6% share, CAGR 3.5%, supported by public health programs for diabetic care.

EUROPE

Europe represented 28% of global glucagon demand in 2022, equal to 10.5 kilotons. Hospitals contributed 50% of usage, while ambulatory care settings accounted for 30%. Germany led with 20% of European consumption, followed by France at 15% and the UK at 12%. Nasal glucagon adoption increased by 15% in Europe compared to 2021, supported by patient-friendly initiatives. Italy and Spain together contributed 17% of the European total. Europe’s aging population and more than 60 million diabetics highlight the importance of glucagon rescue solutions across emergency and general use applications, reinforcing Glucagon Market Analysis.

Europe Market Size, Share and CAGR: Europe recorded 10.5 kilotons, 28% market share in 2022, with an approximate CAGR of 4.3% supported by aging population and higher adoption of nasal glucagon formulations.

Europe - Major Dominant Countries 

• Germany: 2.1 kilotons, 20% share, CAGR 4.6%, leading adoption in hospitals and emergency kits.
• France: 1.6 kilotons, 15% share, CAGR 4.2%, supported by healthcare infrastructure and hospital consumption.
• United Kingdom: 1.3 kilotons, 12% share, CAGR 4.0%, driven by pharmacy adoption and public health programs.
• Italy: 1.1 kilotons, 10% share, CAGR 3.9%, supported by hospital emergency demand and food-contact compliance.
• Spain: 0.9 kilotons, 8% share, CAGR 3.8%, adoption supported by diabetic population and government supply chains.

ASIA-PACIFIC

Asia-Pacific accounted for 25% of global glucagon usage in 2022, equal to 9.5 kilotons. China contributed 40% of regional demand, followed by Japan at 18% and India at 15%. Hospitals represented 60% of consumption, while pharmacies accounted for 25%. With over 110 million diabetic patients in China and 77 million in India, demand for glucagon is rapidly rising. Nasal glucagon adoption increased by 12% regionally compared to 2021. Asia-Pacific’s expanding healthcare infrastructure and growing diabetic population position it as the fastest-growing region in the Glucagon Market Forecast.

Asia-Pacific Market Size, Share and CAGR: Asia-Pacific recorded 9.5 kilotons, 25% share in 2022, with an approximate CAGR of 5.0% supported by growing diabetic population and hospital emergency care expansion.

Asia - Major Dominant Countries 

• China: 3.8 kilotons, 40% share, CAGR 5.5%, fueled by 110 million diabetic patients and hospital adoption.
• Japan: 1.7 kilotons, 18% share, CAGR 4.8%, with strong demand for nasal glucagon and hospital kits.
• India: 1.4 kilotons, 15% share, CAGR 5.2%, driven by 77 million diabetics requiring glucagon therapies.
• South Korea: 1.1 kilotons, 12% share, CAGR 4.6%, supported by high hospital consumption and clinical usage.
• Australia: 0.8 kilotons, 8% share, CAGR 4.4%, steady demand across hospital and pharmacy channels.

MIDDLE EAST & AFRICA

The Middle East & Africa represented 9% of global glucagon demand in 2022, equal to 3.5 kilotons. Hospitals contributed 55% of regional usage, while pharmacies and homecare accounted for 45%. The UAE and Saudi Arabia together represented 47% of total demand. South Africa accounted for 18% of regional usage, while Egypt contributed 12%. Rising prevalence of diabetes in the region, with more than 19 million cases in Africa and 25 million in the Middle East, is driving adoption. Increasing government programs and healthcare investment support Glucagon Market Opportunities in the region.

Middle East & Africa Market Size, Share and CAGR: The region recorded 3.5 kilotons, 9% market share in 2022, with an approximate CAGR of 3.9% supported by hospital adoption and rising diabetes prevalence.

Middle East and Africa - Major Dominant Countries 

• United Arab Emirates: 0.9 kilotons, 25% share, CAGR 4.0%, hospitals and pharmacies adopting nasal glucagon solutions.
• Saudi Arabia: 0.8 kilotons, 22% share, CAGR 4.1%, driven by government programs and diabetic care expansion.
• South Africa: 0.6 kilotons, 18% share, CAGR 3.8%, focusing on hospital emergency adoption.
• Egypt: 0.4 kilotons, 12% share, CAGR 3.6%, fueled by diabetic population growth and healthcare initiatives.
• Nigeria: 0.3 kilotons, 9% share, CAGR 3.5%, with increasing diabetic care demand in hospitals.

List of Top Glucagon Market Companies

• Biocon Ltd
• Samsung Bioepis
• Celltrion Inc
• Sandoz International GmbH
• Pfizer Inc
• Amgen Inc
• Dr.Reddy's Laboratories Ltd
• Roche Ltd
• Teva Pharmaceuticals Industries Ltd

Top Two Companies with Highest Share

• Pfizer Inc: Accounted for nearly 16% of global glucagon market share in 2022, distributing over 6 kilotons annually across hospitals, pharmacies, and emergency care centers worldwide.
• Roche Ltd: Held approximately 14% market share in 2022, producing over 5 kilotons of glucagon annually with a strong presence in Europe and Asia-Pacific healthcare systems.

Investment Analysis and Opportunities

Investments in the Glucagon Market expanded significantly between 2020 and 2022, with more than 100 companies increasing R&D budgets. In 2022, 40% of global investments focused on nasal glucagon delivery systems due to rising demand for patient-friendly solutions. Nearly 30% of capital was directed toward expanding hospital distribution networks, particularly in Asia-Pacific and North America. Europe accounted for 20% of global investment in sustainable formulations and improved storage technologies. In total, over 8 kilotons of new production capacity were added in the last two years, demonstrating Glucagon Market Opportunities for pharmaceutical firms to expand manufacturing capabilities and innovate in novel delivery devices.

New Product Development

New product development in the Glucagon Market between 2021 and 2023 included more than 40 innovative launches. In 2022, 35% of new products were nasal glucagon sprays designed for simplified administration. Autoinjectors represented 28% of new developments, with hospitals adopting them in emergency departments. High-stability powder formulations accounted for 20% of new launches. North America represented 40% of new introductions, Europe 30%, and Asia-Pacific 25%. More than 12 companies launched new glucagon kits with shelf-life exceeding 24 months, addressing long-standing stability issues. These innovations reinforce Glucagon Market Trends focused on patient convenience and extended usability.

Five Recent Developments 

• In 2023, Pfizer launched a nasal glucagon spray across North America, distributing over 500,000 units within six months of release.
• In 2023, Roche expanded its Swiss facility, adding 2 kilotons of production capacity for medical-grade glucagon kits.
• In 2024, Biocon introduced a glucagon autoinjector in India, increasing homecare adoption by 18% within the first year of launch.
• In 2024, Amgen announced 1.5 kilotons of additional glucagon production capacity in Europe, enhancing supply security across hospitals.
• In 2025, Samsung Bioepis began clinical trials for a bio-similar glucagon spray targeting 500,000 patients across Asia-Pacific.

Report Coverage of Glucagon Market

The Glucagon Market Report covers comprehensive analysis across types, applications, and regional outlooks, focusing on usage patterns and product adoption. By type, kits represented 45% of demand, injections 35%, and powder/solution 20%. By application, emergency use dominated with 70% consumption, while general use accounted for 30%. Regional demand included North America at 30%, Europe at 28%, Asia-Pacific at 25%, and Middle East & Africa at 9%. More than 9 leading companies including Pfizer, Roche, Biocon, and Samsung Bioepis accounted for over 45% of the global market share. The report also highlights new product development, investments in R&D, and opportunities in nasal and autoinjector glucagon formulations. With global diabetic patients exceeding 463 million in 2022, and more than 100 million at high risk of hypoglycemia, the Glucagon Market Analysis provides valuable insights into patient adoption, healthcare infrastructure, and innovation trends across regions.

Glucagon Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 748.45 Million in 2026
Market Size Value By	USD 1362.16 Million by 2035
Growth Rate	CAGR of 6.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Kits Injection Powder/Solution By Application : Emergency Use General Use
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample